查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017523

藥物濫用治療市場：按治療形式、藥物類型、服務提供者、支付方式和最終用戶分類－2026-2032年全球市場預測

Substance Abuse Treatment Market by Treatment Mode, Substance Type, Service Provider, Payment Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物濫用治療市場價值將達到 130.4 億美元，到 2026 年將成長至 139.3 億美元，到 2032 年將達到 213.2 億美元，複合年成長率為 7.26%。

主要市場統計數據
基準年 2025 130.4億美元
預計年份：2026年 139.3億美元
預測年份 2032 213.2億美元
複合年成長率 (%) 7.26%

在現代醫療保健轉型、政策轉變和以患者為中心的護理重點不斷發展的背景下，策略性地引入藥物濫用治療

目前藥物濫用治療處於臨床照護、公共和社會福利服務的關鍵交匯點，需要採取精細的實施方案，以應對當前挑戰並把握機遇，同時兼顧更廣泛的醫療保健系統轉型。近年來，醫療服務提供者和保險公司已做出相應調整，以適應不斷變化的患者期​​望、技術進步和監管重點。本導言概述了構成未來分析基礎的基本趨勢和挑戰。

分析結構和技術變革，這些變革將重組整個成癮治療服務體系、人力資源模式以及支付方與服務提供者之間的合作。

目前，藥物濫用治療正經歷著由技術普及、人員重新部署和政策調整所驅動的變革，這些變革共同重塑了醫療保健的獲取途徑和治療的連續性。遠端醫療的擴展正從一次性諮詢轉向支援非同步互動和同步治療的整合虛擬平台，從而實現了急性戒斷、住院穩定治療和門診復健服務之間的連續性。同時，用於病患監測和遠端諮詢的數位化工具正在為早期療育和長期支持開闢新的途徑，這反過來又需要對臨床方案和報銷模式進行更新。

對 2025 年關稅變化將如何影響美國各地成癮治療機構的供應鏈、籌資策略和資本規劃進行全面評估。

美國於2025年實施的收費調整的累積影響正對藥物濫用治療機構及其輔助服務提供者的供應鏈和採購慣例產生廣泛的連鎖反應。進口醫療設備、數位硬體和某些藥品成分的關稅調整提高了部分治療系統和監測設備的單位成本，迫使服務提供者重新調整其設備採購計畫和庫存策略。那些依賴國內無法大規模生產的專用戒毒設備、遠端監測設備和遠端醫療周邊設備的機構，受到的壓力尤其顯著。

詳細的細分洞察，闡明治療模式、特定藥物的臨床路徑、提供者類型、最終用戶人口統計特徵和支付模式，將指南策略制定。

細分分析揭示了不同治療模式和方法在臨床服務提供、資源投入和患者體驗方面的顯著差異。根據治療模式，護理路徑包括日間護理、戒毒治療、住院治療、門診治療和遠端醫療。戒毒治療進一步細分為藥物戒毒和非藥物戒毒；住院治療分為醫院住院治療和康復住宅住院治療；門診服務分為強化門診項目和標準門診項目；遠端醫療涵蓋非同步和同步模式。這些差異會影響臨床人員編制模式、監管合規要求和資本投入，因為藥物戒毒和醫院住院治療需要更高的臨床能力和基礎設施，而住宅住院治療和門診計畫則更注重社會心理支持和社區融入。

對美洲、歐洲、中東和非洲以及亞太地區的監管、贖回和交付系統進行區域分析，以指南投資決策。

區域趨勢揭示了政策環境、服務基礎設施和人力資源可用性方面的差異，這些差異對美洲、歐洲、中東和非洲以及亞太地區的醫療服務提供產生了重大影響。在美洲，採用遠端醫療和整合式醫療模式的獎勵因法律規範和支付方結構而異。同時，都市區地區通常擁有先進的臨床項目和數位平台來支援持續性醫療服務。在歐洲、中東和非洲，不同的公共資金籌措體系和社區基礎設施發展水準的差異，使得專案設計必須靈活，能夠在資源有限的環境中可擴展，並與國家衛生優先事項保持一致。在亞太地區，快速的數位化和私營部門的積極參與正在推動混合醫療模式的發展，但都市區醫療服務取得的差距仍然是一個持續存在的挑戰。

企業層面的洞察，著重於整合策略、數位參與模式和夥伴關係方式，從而在護理連續性方面帶來可衡量的改進。

在藥物濫用治療領域，領先的機構正透過整合臨床服務、與保險公司和社區網路夥伴關係以及投資數位互動平台來脫穎而出。將住院和門診路徑與家庭護理相結合的醫療保健系統和醫院中心正在減少護理碎片化並提高護理的連續性。建立健全的轉診網路和可衡量結果框架的獨立復健中心和診所更有能力向保險公司和簽約合作夥伴證明其價值。同時，支持非同步認知行為療法和同步療法的遠端醫療平台提供者正在創造新的互動途徑，並為以前面臨地理或時間安排障礙的人們擴大服務範圍。

為醫療保健領導者提供可操作且優先考慮的建議，以增強護理的連續性、員工的韌性、採購的穩定性以及與支付方一致的結果衡量。

產業領導者應制定一套切實可行的優先事項，以協調臨床卓越性、營運韌性和支付方期望。首先，投資建置可互通的數位化平台，連結戒毒、住院、門診和遠端醫療服務，確保護理流程無縫銜接，減少繁瑣的行政流程。其次，積極重新設計人員配備模式，透過交叉培訓、遠端監督以及相關醫療專業人員的角色調整來擴大服務能力，以應對人員短缺問題，同時維持服務品質。第三，建構以支付方為導向的績效評估框架，透明地追蹤患者留存率、復發指標和功能恢復指標，以支持就全面或以價值主導的報銷協議進行協商。

採用透明的混合方法研究設計，結合質性訪談、二手文獻整合和情境分析，以檢驗對治療生態系統的見解。

本分析的調查方法結合了多種研究手段，旨在建構對藥物濫用治療生態系統的全面、多維度且檢驗的理解。研究人員首先對臨床負責人、計畫主管、支付方、數位醫療供應商和社區相關人員進行了定性訪談，以了解實際運作和新興的最佳實踐。其次，研究人員系統性地回顧了臨床指南、政策綱要和同行評審文獻，將研究結果置於既有證據和法律規範的背景下進行解讀。在整合資料的過程中，研究人員專注於對資訊來源進行交叉檢驗，以最大限度地減少偏差並突出一致的趨勢。

簡潔扼要的結論概述了整合護理、營運韌性和支付方合作的路線圖，以提高治療效果和可及性。

總之，藥物濫用治療領域正處於一個轉折點，數位化創新、保險公司獎勵的轉變、變革性人才的湧現以及供應鏈的現狀交織在一起，蓄勢待發，即將重塑服務提供模式。涵蓋從醫療戒斷到持續門診治療和遠端醫療支援的整合式護理路徑，為治療的連續性和療效的提升提供了最有前景的途徑。然而，要實現這一目標需要醫療服務提供者、保險公司和技術合作夥伴之間的策略協作，以及在人才培養和採購韌性方面的營運投入。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按治療方法分類的藥物濫用治療市場

  • 日托
  • 排毒
    • 醫療戒毒
    • 非醫療戒毒
  • 住院治療
    • 醫院住院治療
    • 住宅治療
  • 門診
    • 強化門診治療計劃
    • 標準門診計劃
  • 遠端醫療
    • 非同步遠端醫療
    • 同步遠端醫療

第9章：按物質類型分類的藥物濫用治療市場

  • 酒精
  • 大麻
  • 鴉片類藥物
  • 甲基安非他命

第10章：按服務提供者分類的藥物濫用治療市場

  • 診所
  • 居家照護
  • 醫院設施
  • 獨立復健中心

第11章 藥物濫用治療市場：以支付方式分類

  • 私人保險
  • 公共資金
  • 自費

第12章 藥物濫用治療市場：依最終使用者分類

  • 青年
  • 成人
  • 老年人

第13章 藥物濫用治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 藥物濫用治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 藥物濫用治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國藥物濫用治療市場

第17章：中國藥物濫用治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Acadia Healthcare Company, Inc.
  • Advanced Recovery Systems, LLC
  • American Addiction Centers, Inc.
  • Caron Treatment Centers, Inc.
  • CleanSlate Centers, LLC
  • Hazelden Betty Ford Foundation
  • Odyssey House, Inc.
  • Orexo AB
  • Phoenix House Foundation
  • Recovery Centers of America, LLC
  • Universal Health Services, Inc.
Product Code: MRR-0376B2CAB002

The Substance Abuse Treatment Market was valued at USD 13.04 billion in 2025 and is projected to grow to USD 13.93 billion in 2026, with a CAGR of 7.26%, reaching USD 21.32 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.04 billion
Estimated Year [2026] USD 13.93 billion
Forecast Year [2032] USD 21.32 billion
CAGR (%) 7.26%

A strategic introduction that frames substance abuse treatment within contemporary healthcare transformation, policy shifts, and evolving patient-centered care priorities

The substance abuse treatment landscape occupies a pivotal intersection of clinical care, public policy, and social services, demanding a nuanced introduction that frames current pressures and opportunities within a broader health system transformation. In recent years, providers and payers have adapted to changing patient expectations, technological advances, and evolving regulatory priorities, and this introduction outlines the foundational trends and questions that inform the analysis ahead.

This overview highlights how clinical pathways, workforce capacity, reimbursement constructs, and patient engagement models are converging to reshape treatment delivery. It situates key stakeholder motivations-from clinicians and health systems to payers and community organizations-and explains why integrated approaches that bridge acute detoxification, inpatient stabilization, outpatient recovery, and telehealth-enabled continuity are now central to effective care. By establishing this context, readers are positioned to understand subsequent sections that explore structural shifts, policy impacts, segmentation insights, regional dynamics, and practical recommendations for leaders seeking durable improvements in outcomes and operational resilience.

An analysis of the structural and technological shifts reshaping addiction treatment delivery, workforce models, and payer-provider collaboration across care continuums

The landscape of substance abuse treatment is undergoing transformative shifts driven by technology diffusion, workforce realignment, and policy recalibration that together are redefining access and the continuum of care. Telehealth expansion has moved beyond episodic consultations to integrated virtual platforms that support asynchronous engagement and synchronous therapy, enabling continuity between acute detoxification, inpatient stabilization, and outpatient recovery services. At the same time, digital tools for patient monitoring and remote counseling are creating new pathways for earlier intervention and longitudinal support, which in turn require updated clinical protocols and reimbursement models.

Concurrently, provider networks are rethinking capacity and care mix, balancing hospital-based inpatient services with residential programs and intensive outpatient models designed to reduce readmissions and improve retention. Payment models are evolving to emphasize value-based outcomes and bundled approaches, prompting providers to forge deeper collaborations with payers and community-based organizations. Workforce constraints, especially among licensed addiction specialists and behavioral health clinicians, are spurring task-shifting strategies, augmented by tele-supervision and training delivered remotely. Taken together, these shifts are producing a more hybridized service architecture that demands flexible operational design and an emphasis on interoperability, patient engagement, and outcome measurement.

A comprehensive assessment of how 2025 tariff changes altered supply chains, procurement strategies, and capital planning for addiction treatment providers nationwide

The cumulative impact of the United States tariff changes introduced in 2025 has reverberating implications across supply chains and procurement practices relevant to substance abuse treatment providers and ancillary service suppliers. Tariff adjustments on imported medical equipment, digital hardware, and certain pharmaceutical components have increased unit costs for some therapeutic delivery systems and monitoring devices, prompting providers to reassess capital purchasing plans and inventory strategies. These pressures have been felt most acutely in settings that depend on specialized detoxification equipment, remote monitoring devices, and telehealth peripherals that are not domestically manufactured at scale.

In response, healthcare organizations and supply chain managers have accelerated diversification strategies, forging relationships with alternative vendors, negotiating longer-term contracts to hedge price volatility, and prioritizing total cost of ownership in procurement decisions. Some systems have shifted to pooled purchasing arrangements and leveraged group purchasing organizations to obtain volume discounts and mitigate tariff-driven increases. Meanwhile, payers and public funding bodies are reviewing reimbursement codes and capital allowances to accommodate rising operational costs, which influences where providers invest in equipment versus staffing. Importantly, these tariff-induced dynamics have also catalyzed conversations about domestic manufacturing capacity for critical devices and the need for resilient supply chain design that supports continuity of care.

Deep segmentation insights that delineate treatment modes, substance-specific clinical pathways, provider typologies, end-user cohorts, and payment modalities to inform strategy

Segmentation analysis reveals meaningful differences in clinical delivery, resource intensity, and patient experience across treatment modes and modalities. Based on treatment mode, care pathways include day treatment, detoxification, inpatient, outpatient, and telehealth, with detoxification further divided into medical detox and non-medical detox, inpatient care differentiated between hospital-based inpatient and residential inpatient settings, outpatient services characterized as intensive outpatient program and standard outpatient program, and telehealth encompassing asynchronous and synchronous modalities. These distinctions influence clinical staffing models, regulatory compliance needs, and capital investments, as medical detox and hospital-based inpatient settings require higher clinical acuity and infrastructure, while residential inpatient and outpatient programs place greater emphasis on psychosocial supports and community reintegration.

Looking at substance type, treatment approaches vary across alcohol, cannabis, opioids, and stimulants, with pharmacotherapy and harm reduction strategies playing larger roles in some cohorts while behavioral interventions remain central across all. Service provider segmentation highlights operational contrasts between clinics, homecare providers, hospital-based centers, and standalone rehab centers, each with differing referral patterns and payer interactions. End-user segmentation into adolescents, adults, and geriatric cohorts underscores the need for age-appropriate clinical protocols and social supports. Finally, payment mode distinctions between private insurance, public funding, and self-pay shape access dynamics, authorization timelines, and revenue cycles. Integrating these layered segments provides a granular view of demand drivers, clinical priorities, and operational levers that providers and payers can use to tailor programs and improve patient retention and outcomes.

Regional intelligence that contrasts regulatory, reimbursement, and delivery dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific to guide investment decisions

Regional patterns reveal differentiated policy environments, service infrastructures, and workforce availability that materially affect care delivery across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory frameworks and payer mixes create varied incentives for adoption of telehealth and integrated care models, while concentrated urban centers often host advanced clinical programs and digital platforms that support continuity of care. Moving across to Europe, Middle East & Africa, diverse public funding arrangements and varying levels of community-based infrastructure necessitate flexible program designs that can scale in resource-constrained settings and align with national health priorities. In the Asia-Pacific region, rapid digital adoption and significant private sector involvement are driving blended care models, though urban-rural disparities in access remain a persistent challenge.

These regional variations influence where investments in workforce training, telehealth infrastructure, and residential capacity will be most impactful. Cross-border collaborations and international knowledge exchange are increasingly important to transfer best practices, particularly in areas such as pharmacotherapy regulation, detoxification protocols, and outcome measurement frameworks. Understanding these geographic nuances allows policymakers, payers, and providers to prioritize interventions that match local regulatory conditions, cultural expectations, and existing service ecosystems while enabling targeted partnerships that bridge capability gaps.

Company-level insights highlighting integration strategies, digital engagement models, and partnership approaches that drive measurable improvements in care continuity

Leading organizations in the substance abuse treatment space are differentiating through integration of clinical services, partnerships with payers and community networks, and investment in digital engagement platforms. Health systems and hospital-based centers that align inpatient and outpatient pathways with home-based supports are reducing fragmentation and improving continuity of care. Standalone rehab centers and clinics that develop robust referral networks and measurable outcome frameworks are better positioned to demonstrate value to payers and contracting partners. At the same time, telehealth platform providers that support both asynchronous cognitive behavioral interventions and synchronous therapy have created new corridors for engagement, expanding access for populations who previously faced geographic or scheduling barriers.

Strategic collaborations between service providers and pharmacy, laboratory, and remote-monitoring vendors are enhancing clinical capability without requiring extensive in-house capital. Organizations that prioritize clinician training, evidence-based protocols, and outcome tracking are more successful in negotiating value-oriented reimbursement arrangements. Moreover, companies that invest in culturally competent care models and age-specific programming for adolescents and geriatrics are addressing unmet needs and differentiating in competitive referral markets. Overall, firms that combine operational agility with strong data governance and interoperability are emerging as preferred partners for public and private payers seeking accountable care solutions.

Practical and prioritized recommendations for healthcare leaders to strengthen care continuity, workforce resilience, procurement stability, and payer-aligned outcome measurement

Industry leaders should adopt a set of actionable priorities that align clinical excellence with operational resilience and payer expectations. First, invest in interoperable digital platforms that connect detoxification, inpatient, outpatient, and telehealth services to ensure seamless transitions of care and reduce administrative friction. Second, proactively redesign workforce models to expand capacity through cross-training, tele-supervision, and allied health roles that maintain quality while addressing staffing shortages. Third, build payer-facing outcome frameworks that transparently track retention, relapse indicators, and functional recovery metrics to support negotiations for bundled or value-driven reimbursement arrangements.

Additionally, organizations should diversify procurement strategies to mitigate supplier disruptions caused by external trade changes, including long-term contracting, pooled purchasing, and supplier qualification protocols that emphasize total cost of ownership. Prioritize the development of age-specific programs and culturally adapted interventions to improve engagement for adolescents and geriatric populations. Finally, pursue targeted partnerships with technology vendors to scale asynchronous and synchronous telehealth offerings, while implementing governance policies that protect patient privacy and ensure clinical safety. These steps, when implemented cohesively, will strengthen clinical outcomes, stabilize finances, and create a foundation for sustainable growth in a rapidly evolving landscape.

A transparent mixed-methods research design integrating qualitative interviews, secondary literature synthesis, and scenario analysis to validate treatment ecosystem insights

The research methodology underpinning this analysis combined mixed-methods approaches to produce a robust, triangulated understanding of the substance abuse treatment ecosystem. Primary qualitative interviews were conducted with clinical leaders, program directors, payers, digital health vendors, and community stakeholders to capture on-the-ground operational realities and emergent best practices. Secondary research involved systematic review of clinical guidelines, policy briefs, and peer-reviewed literature to situate findings within established evidence and regulatory frameworks. Data synthesis emphasized cross-validation across sources to minimize bias and highlight consistent trends.

Analytical techniques included thematic coding of qualitative inputs, scenario analysis to assess the implications of policy and trade shifts, and comparative profiling of service modalities and regional infrastructures. Special attention was given to segmentation variables-treatment mode, substance type, service provider, end-user cohorts, and payment mode-to ensure that insights were actionable at a programmatic level. Ethical considerations and data privacy standards guided the handling of interview material, and findings were subjected to peer review within the research team to reinforce analytical rigor and transparency.

A concise conclusion synthesizing pathways for integrated care, operational resilience, and payer collaboration to advance treatment effectiveness and accessibility

In conclusion, the substance abuse treatment field stands at an inflection point where digital innovation, shifting payer incentives, workforce transformation, and supply chain realities are intersecting to reshape service delivery. Integrated care pathways that span medical detoxification through sustained outpatient and telehealth support offer the most promise for improving continuity and outcomes. However, achieving this requires strategic alignment across providers, payers, and technology partners, as well as operational investments in workforce development and procurement resilience.

Moving forward, stakeholders that prioritize interoperable systems, outcome-driven contracting, and age- and culturally tailored programs will be best positioned to respond to policy shifts and to serve diverse patient populations effectively. The cumulative impacts of regulatory and trade dynamics underscore the need for adaptive planning and collaborative purchasing models. Ultimately, a coordinated approach that balances clinical quality, financial sustainability, and patient-centered design will be essential to advancing the effectiveness and reach of substance abuse treatment services.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Substance Abuse Treatment Market, by Treatment Mode

  • 8.1. Day Treatment
  • 8.2. Detoxification
    • 8.2.1. Medical Detox
    • 8.2.2. Non Medical Detox
  • 8.3. Inpatient
    • 8.3.1. Hospital Based Inpatient
    • 8.3.2. Residential Inpatient
  • 8.4. Outpatient
    • 8.4.1. Intensive Outpatient Program
    • 8.4.2. Standard Outpatient Program
  • 8.5. Telehealth
    • 8.5.1. Asynchronous Telehealth
    • 8.5.2. Synchronous Telehealth

9. Substance Abuse Treatment Market, by Substance Type

  • 9.1. Alcohol
  • 9.2. Cannabis
  • 9.3. Opioids
  • 9.4. Stimulants

10. Substance Abuse Treatment Market, by Service Provider

  • 10.1. Clinic
  • 10.2. Homecare
  • 10.3. Hospital Based Centre
  • 10.4. Standalone Rehab Center

11. Substance Abuse Treatment Market, by Payment Mode

  • 11.1. Private Insurance
  • 11.2. Public Funding
  • 11.3. Self Pay

12. Substance Abuse Treatment Market, by End User

  • 12.1. Adolescents
  • 12.2. Adults
  • 12.3. Geriatric

13. Substance Abuse Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Substance Abuse Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Substance Abuse Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Substance Abuse Treatment Market

17. China Substance Abuse Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Acadia Healthcare Company, Inc.
  • 18.6. Advanced Recovery Systems, LLC
  • 18.7. American Addiction Centers, Inc.
  • 18.8. Caron Treatment Centers, Inc.
  • 18.9. CleanSlate Centers, LLC
  • 18.10. Hazelden Betty Ford Foundation
  • 18.11. Odyssey House, Inc.
  • 18.12. Orexo AB
  • 18.13. Phoenix House Foundation
  • 18.14. Recovery Centers of America, LLC
  • 18.15. Universal Health Services, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DAY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DAY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DAY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY MEDICAL DETOX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY MEDICAL DETOX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY MEDICAL DETOX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY NON MEDICAL DETOX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY NON MEDICAL DETOX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY NON MEDICAL DETOX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOSPITAL BASED INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOSPITAL BASED INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOSPITAL BASED INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY RESIDENTIAL INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY RESIDENTIAL INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY RESIDENTIAL INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INTENSIVE OUTPATIENT PROGRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INTENSIVE OUTPATIENT PROGRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INTENSIVE OUTPATIENT PROGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STANDARD OUTPATIENT PROGRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STANDARD OUTPATIENT PROGRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STANDARD OUTPATIENT PROGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ASYNCHRONOUS TELEHEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ASYNCHRONOUS TELEHEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ASYNCHRONOUS TELEHEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SYNCHRONOUS TELEHEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SYNCHRONOUS TELEHEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SYNCHRONOUS TELEHEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ALCOHOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ALCOHOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ALCOHOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY CANNABIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY CANNABIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY CANNABIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STIMULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOSPITAL BASED CENTRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOSPITAL BASED CENTRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY HOSPITAL BASED CENTRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STANDALONE REHAB CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STANDALONE REHAB CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY STANDALONE REHAB CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PUBLIC FUNDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PUBLIC FUNDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PUBLIC FUNDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SELF PAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SELF PAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SELF PAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 188. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 189. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 190. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 192. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 218. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 219. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 220. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 222. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 228. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 229. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 230. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 232. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 233. NATO SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY DETOXIFICATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY TELEHEALTH, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SUBSTANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY PAYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA SUBSTANCE ABUSE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)